Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-valent influenza vaccine (MDCK cell)
- Development stage
- Preclinical
- Lead developer
- AIM Vaccine Co.
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The 4-valent influenza vaccine (MDCK cell) is a quadrivalent inactivated viral vaccine currently in preclinical development by AIM Honesty, a subsidiary of AIM Vaccine Co., Ltd. Unlike traditional influenza vaccines produced in embryonated chicken eggs, this vaccine utilizes Madin-Darby Canine Kidney (MDCK) cell culture technology for manufacturing. This cell-based production platform is designed to offer higher safety and potentially better antigenic matching by avoiding egg-adaptive mutations that can occur during traditional production. The vaccine is formulated to induce strain-specific protective antibody responses against four influenza strains, typically including two influenza A subtypes and two influenza B lineages, to provide broad protection against seasonal influenza infection.
- Other names
- quadrivalent influenza vaccine (MDCK)4-valent Influenza Vaccine (MDCK cell)AIM Honesty quadrivalent influenza vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on 4-valent influenza vaccine (MDCK cell).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-valent influenza vaccine (MDCK cell).